Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer

Clinical Cancer Research

Volumn 16, Issue 19, 2010, Pages 4702-4710

  Anders, Carey K ^a   Winer, Eric P ^b   Ford, James M ^c   Dent, Rebecca ^d   Silver, Daniel P ^b   Sledge, George W ^e   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIS 201; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CAPECITABINE; CARBOPLATIN; CEP 9272; CISPLATIN; ESTROGEN RECEPTOR; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HISTONE H2AX; ID4 PROTEIN; INO 1001; IXABEPILONE; MK 482; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PROTEIN; RAD51 PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DEATH; CLINICAL TRIAL; CONSTIPATION; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRAND BREAK REPAIR; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EXCISION REPAIR; FATIGUE; FRAMESHIFT MUTATION; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; LETHALITY; MISMATCH REPAIR; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77957599220     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0939     Document Type: Review

References (51)

1. Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. Proceedings of the Annual Meeting of the American Society for Clinical Oncology; Clinical Science Symposium; 2008 Jun 3; Chicago.
2. Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
3. Dent R, Trudeau M, Pritchard K, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
4. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71. (Pubitemid 43117611)
5. Millikan RC, Newman B, Tse C-K, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
6. Nielsen TO, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74. (Pubitemid 39100473)
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
8. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23. (Pubitemid 36842560)
10. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
11. Burstein HJ. Therapeutic options for treatment refractory breast cancer: discussion. Proceedings of the Annual Meeting of the American Society for Clinical Oncology; Metastatic Breast Cancer Oral Abstract Presentation; 2010 Jun 8; Chicago.
12. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
13. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer high incidence of central nervous system metastases. Cancer 2008;113:2638-45.
14. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27:[Abstract 3].
15. O'Shaughnessy J, Yoffe M, Osborne C, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. San Antonio Breast Cancer Symposium. 2008:Abstract 2120.
16. Ford J. DNA damage response pathways and cancer. In: Abeloff MD, editor. Clinical oncology. 3rd ed. New York: Churchill Livingstone; 2004.
17. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002;32:180-4.
18. Zhang J, Powell S. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005;3:531-9. (Pubitemid 41567272)
19. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72. (Pubitemid 32206494)
20. Cousineau I, Belmaaza A. BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 2007;6:962-71. (Pubitemid 46658751)
21. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91.
22. Snouwaert JN, Gowen LC, Latour AM, et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999;18:7900-7.
23. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002;2:113-23.
24. Narod SA, Foulkes W. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
25. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharm Res 2005;52:25-33. (Pubitemid 40725597)
26. Tentori L, Porarena I, Graziani G. Potential clinical applications of poly (ADP-ribose) polymerase inhibitors. Pharm Res 2002;45:73-85. (Pubitemid 35425647)
27. Plummer E. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006;6:364-8.
28. Cleator S, Heller W, Coombes R. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44. (Pubitemid 46291713)
29. Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
30. Turner NC, Reis-Filho J, Russell A, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32. (Pubitemid 46514749)
31. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-89.
32. Grushko T, Nwachukwu C, Caroenthammaraksa S, et al. Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancer. J Clin Oncol 2010;28:[Abstract 10510].
33. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
34. Fong PC, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
35. O'Shaughnessy J, Osborne C, Pippen J, et al. Updated results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastastic triple-negative breast cancer. Cancer Res 2009;69: [Abstract 3122].
36. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27:[Abstract CRA501].
37. Bryant HE, Schultz N, Thomas H, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
38. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
39. Silver DP, Richardson A, Eklund A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
40. Alli E, Sharma V, Sunderesakumar P, Ford J. Defective repair of oxidative DNA damage in triple negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009;69:3589-96.
41. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin. Cancer Res 2010 Aug 26. [Epub ahead of print] PMID: 20798217. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20798217.
42. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27:CRA501.
43. Gelmon K, Hirte H, Robidoux A, et al. Can we define tumors that respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol 2010;28:[Abstract 3002].
44. Dent R, Lindeman G, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010;28:1018.
45. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008;26:[Abstract 3577].
46. Mahany J, Lewis N, Heath E, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008;26:[Abstract 3579].
47. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
48. Edwards SL, Brough R, Lord C, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-6.
49. Swisher EM, Sakai W, Karlan B, Wurz K, Urban N, Toshiyasu T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68:2581-6.
50. Rodriguez A, Rimawi M, Wu M, et al. A BRCA1-like, 25-gene assay predicts for anthracycline-chemosenstivity in sporadic triple-negative breast cancer. 2009 San Antonio Breast Cancer Symposium 2009:Abstract 110.
51. Comen EA, Robson M. Inhibitionof poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology 2010;24:55-68.